Celgene Corp.

NAS : CELG
Pharmaceuticals
Summit NJ
IW Best50N/A
2012 Revenue (US$ Millions)$5,507
2011 Revenue (US$ Millions)$4,842
Revenue Growth (%)13.73%
Net Income (US$ Millions)$1,456
Common Shares Outstanding (Millions)$420
Earnings Per Share (US$)$3.30
Total Equity (US$ Millions)$5,694
Profit Growth (%)10.47
Profit Margin (%)26.44%
Return On Equity (%)26.41%
Long Term Debt (US$ Millions)$2,771
Debt To Equity Ratio (%)0.49%
Market Capitalization (US$ Millions)$32,938
Total Assets (US$ Millions)$11,734
Return on Assets (%)14.55
Current Assets (US$ Millions)$5,534
Inventories (US$ Millions)$259
Current Liabilities (US$ Millions)$1,690
Cost of Goods Sold (US$ Millions)$299
Asset Turnover0.47
Inventory Turnover1.33